REGENXBIO Inc. $RGNX Shares Sold by Caliber Wealth Management LLC KS

Caliber Wealth Management LLC KS reduced its position in REGENXBIO Inc. (NASDAQ:RGNX) by 8.5% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 16,095 shares of the biotechnology company’s stock after selling 1,493 shares during the quarter. Caliber Wealth Management LLC KS’s holdings in REGENXBIO were worth $132,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Brooklyn Investment Group increased its stake in REGENXBIO by 163.7% in the 1st quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 3,466 shares during the period. Entropy Technologies LP acquired a new position in REGENXBIO in the 1st quarter valued at $107,000. Wealth Enhancement Advisory Services LLC acquired a new position in REGENXBIO in the 1st quarter valued at $123,000. Pallas Capital Advisors LLC increased its stake in REGENXBIO by 67.1% in the 2nd quarter. Pallas Capital Advisors LLC now owns 17,407 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 6,992 shares during the period. Finally, Corton Capital Inc. increased its stake in REGENXBIO by 54.6% in the 1st quarter. Corton Capital Inc. now owns 20,528 shares of the biotechnology company’s stock valued at $147,000 after buying an additional 7,252 shares during the period. 88.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at REGENXBIO

In related news, CEO Curran Simpson sold 20,811 shares of the business’s stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $12.62, for a total value of $262,634.82. Following the sale, the chief executive officer directly owned 216,162 shares in the company, valued at $2,727,964.44. The trade was a 8.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 36,169 shares of company stock valued at $416,598. 12.79% of the stock is owned by insiders.

REGENXBIO Stock Performance

Shares of NASDAQ RGNX opened at $12.19 on Thursday. The firm has a market capitalization of $615.72 million, a P/E ratio of -3.54 and a beta of 1.17. REGENXBIO Inc. has a one year low of $5.03 and a one year high of $13.39. The company’s fifty day moving average is $9.90 and its two-hundred day moving average is $8.93.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.25). The company had revenue of $21.36 million for the quarter, compared to analysts’ expectations of $40.87 million. REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%. On average, sell-side analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on RGNX. Chardan Capital reissued a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Monday, September 8th. Barclays dropped their price objective on shares of REGENXBIO from $50.00 to $37.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Royal Bank Of Canada dropped their price objective on shares of REGENXBIO from $21.00 to $17.00 and set an “outperform” rating on the stock in a research note on Friday, August 8th. Wall Street Zen cut shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $28.38.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.